A Changing Paradigm: Defining the Future Role of SGLT-2 Inhibitors
Published: 02 September 2021
-
Views:
21680
-
Likes:
7
-
Views:
21680
-
Likes:
7
-
4m 26sPart 3 Q&A
Overview
SGLT-2 inhibitors represent one of the single biggest advances in heart failure practice, but how confident are you when comes to using them in different patients, and what can we reasonably expect in the coming months and years from ongoing trials?
Watch our esteemed faculty – Prof Andrew Coats, Dr Biykem Bozkurt and Prof Carolyn Lam as they summarise the latest SGLT-2 inhibitor data in heart failure and attempt to demystify some important practical points around their use with other agents.
To conclude the session, the panel will consider best practices in light of the evidence and guidance we have available today and how to implement this in practice.
ESC Congress 2021
Key Learning Objectives
- Review recent data from randomised controlled trials and meta-analyses on the use of SGLT-2 inhibitors for HFrEF and HFpEF
- Describe parallel and sequential approaches to HFrEF management
- Recall best practice recommendations using SGLT-2 inhibitors in patients with HFrEF without type-2 diabetes
- Apply appropriate treatment algorithms to the management of HF patients
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners
More from this programme
Part 1
SGLT-2 inhibitors in heart failure: Where are we now and where are we heading?
Part 2
Best practice of SGLT2 inhibitors in HFrEF: A Practical Overview
Faculty Biographies
Andrew JS Coats
Professor of Cardiology and Scientific Director
Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.
Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.
He is an…
Biykem Bozkurt
Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America.
Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair; Vice-Chair of Department of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine.
Carolyn Lam
Professor and Senior Consultant
Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore. Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date.